The DESCAR-T registry was set up at the request of health authorities to improve knowledge about CAR-T cell therapies marketed in France for treating patients with malignant hematology. The objective of this register is to support data on the short- and long-term efficacy and tolerance of these treatments in real life.
Using the data collected, the registry allows projects to be conducted to answer specific research questions. One of these projects focuses on the outcomes and management strategies for patients with large B-cell lymphoma relapsing after CAR-T cell therapy, with CAR-T used as a second-line treatment.
Why is this study implemented?
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Current treatments allow for a cure in most patients. However, for some patients, these treatments are not sufficiently effective. Either the disease does not progress favorably (then referred to as “refractory”), or it relapses after a period of remission. Anti-CD19 CAR-T cell therapies have revolutionized the management of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), offering a new curative treatment option in situations where few treatments are effective.
Some cancers are resistant or return after a period of response to CAR-T treatment. The treatments that are then offered differ and do not always provide a lasting response. The data from the DESCAR-T registry will help refine the therapeutic strategy to be adapted for this population.
What are the objectives of the “LDGCB 2L-Relapses” study ?
Patients for whom second-line CAR-T cells fail represent a particularly difficult subgroup. The aim of “LDGCB 2L-Relapses” is to evaluate the outcomes and the impact of salvage therapies in patients with relapsed DLBCL after treatment with second-line CAR-T cells. The goal of this research is to better define the therapeutic option to offer to patients relapsing after CAR-T.
How will this study be conducted?
This study is conducted by Dr. Vincent CAMUS, hematologist at the Henri Becquerel Center in Rouen, and Dr. Pierre SESQUES, hematologist at CHU Lyon Sud in Pierre Bénite.
This study is based on the analysis of data from the medical records of patients participating in DESCAR-T. These analyses are carried out by members of LYSARC.
The report of this study will be sent to the project leaders, who will only receive descriptive results without individual data. No link can be established between the data contained in the report and the patients whose data is collected in DESCAR-T.
This study, “LDGCB 2L-Relapses,” was initiated in May 2025.
The first results of this study will be presented at an international hematology scientific conference at the end of 2025 and will be used for the preparation of a publication in a scientific medical research journal in 2026.
FOR PATIENTS PARTICIPATING IN DESCAR-T
What does this study mean for you?
This study is only for patients participating in DESCAR-T who have a diffuse large B-cell lymphoma (DLBCL) relapsing after CAR-T therapy, used as second line of treatment.
If you are in this situation and you agree that your data be used for this study, this has no direct implication for you.
In particular, you will not have to answer any additional questionnaire compared to what is already planned as part of your participation in DESCAR-T.
What should you do about this study?
There are two options:
- You are not opposed to the use of your data in the context of this study:
- In this case, you don’t have to do anything
- You wish to object to the use of your data in the context of this study:
- In this case, you must inform the doctor who suggested you participate in the DESCAR-T You can also notify your decision by writing an email to the following address: dpo@lysarc.org.
You will find detailed information about your rights to object to the use of your data in the information provided to you when you agreed to participate in DESCAR-T.